NEW ORLEANS—Salvage cryoablation outcomes are similar for prostate cancer patients who fail primary treatment with either external beam radiation therapy (EBRT) or brachytherapy, study findings presented at the 2015 American Urological Association annual meeting suggest.
At 5 years, 60.2% of patients who received cryoablation after EBRT and 47.7% of those who received cryoablation after brachytherapy were free of biochemical failure as defined by Phoenix criteria, according to Matthew D. Ingham, MD, of Eastern Virginia Medical School in Norfolk, Va., and colleagues. The difference between the groups was not statistically significant.
Urinary retention rates at 12 months were higher in EBRT than brachytherapy group (20% vs. 10%), but the groups had similar rates of other complications.
The study included 614 patients who failed EBRT and 112 who failed primary brachytherapy. The groups had a mean age of 71.2 and 69.2 years, respectively.